111 results about "Exocytosis" patented technology

A neurotrophic factor production promoting device is provided, which is able to promote production of a neurotrophic factor or neurotrophic factor-like substance in an affected area by a simple technique that, regardless of the place of treatment, can be performed without transplantation of cells or injection into the affected area, in order to prevent or treat various diseases such as brain diseases. In order to apply a high frequency alternating magnetic field in the range of 20 MHz to 180 MHz, 280 MHz to 600 MHz, or 700 MHz to 1000 MHz to cells at a magnetic flux density of no more than 0.01 Tesla, the neurotrophic factor production promoting device includes a high frequency electromagnetic wave generating means generating a high frequency electromagnetic wave of the abovementioned frequency, in which the magnetic stimulation by the high frequency alternating electromagnetic field of the abovementioned high frequency allows the intracellular concentration of calcium ions to be increased so that exocytosis of the neurotrophic factor group is induced, and the magnetic stimulation allows messenger ribonucleic acid (mRNA) of the neurotrophic factor group to be increased in the cells so that the synthesis and extracellular release of the neurotrophic factor group are promoted.

The invention discloses an exosome-encapsulated nano drug-loading system for tumor treatment, and preparation thereof. The system is obtained by utilizing cell endocytosis of a drug-loading nanometermaterial and then exocytosis. The drug-loading nanometer material is loaded with an antitumor medicine including at least one of a chemotherapeutic, a medicine used for immunotherapy and a medicine used for modifying a tumor microenvironment. The composition, structure and the like of the key outer component biofilm encapsulating the nano drug-loading system are improved, and compared with the prior art, the exosome-encapsulated nano drug-loading system provides a novel route for biofilm-based biological processed nanoparticles. By utilization of the exosome-encapsulated nano drug-loading system, the composition and the structure of the exosome can be maintained greatly, and the obtained exosome-encapsulated nano drug-loading system has good stability and tumor targeting performance duringblood circulation. .

Disclosed herein are multimeric molecular complexes and compounds that are multivalent, i.e., they have two or more targeting elements directed to a ligand that confers paracellular transporting properties and/or transcytotic properties to complexes and compounds to which it is bound. The complexes and compounds have properties that are different from the properties of monomers, complexes and compounds having only one targeting element directed to a paracellular and/or transcytotic ligand. The complexes and compounds of the invention undergo endocytosis, transcytosis and exocytosis; following endocytosis, the complexes or compounds may be transported into the cytosol or an organelle of a cell. In polarized cells, transcytosis can proceed in a “forward” or “reverse” direction. Reverse transcytosis is used for the non-invasive delivery of biologically active agents from the lumen of, e.g., the gastrointestinal tract or the airways of lungs, to the circulatory system. The complexes and compounds are incorporated in various compositions and medical devices suitable for medicinal or veterinary use.

The invention discloses functional albumin and a preparation method of a nano preparation of the functional albumin. The nano preparation of the functional albumin consists of the functional albumin, metal ions and a drug; the metal ions can simultaneously form coordination bonds with the functional albumin and the drug, and can form nanoparticles through induced self-assembly. The nano preparation, through an endocytosis mediated by an albumin receptor (SPARC) on the surface of tumor cells, can deliver the drug into the drug-resistant tumor cells, so as to effectively avoid the exocytosis effect of a p-gp pump on the drug, and then as the coordination bonds break in an acid tumor cell environment through a pH responsibility, the drug releases in cytoplast, enters cell nucleus and inlays in DNA so as to inhibit the synthesis of nucleic acid; and therefore, the growth of the tumor cells is inhibited. Through in vitro characterization, the nano preparation can achieve the relatively good pH responsibility; and through activity evaluation on a cellular level, the system is capable of effectively delivering the drug into the cells, so as to achieve relatively good pH responsive release.

Provided are methods for producing and screening proliferated populations of CD34-negative progenitor cells, mucosal mast cells, connective tissue-type mast cells and basophil cells. The methods generate uniform proliferated populations of cells. The proliferated populations contain a uniform population of a size suitable for use in high throughput screening methods, for example, screening for agents that alter exocytosis. The invention includes screening the proliferated populations with at least one candidate bioactive agent, and evaluating the cells to detect a cell with an altered phenotype. The invention also includes isolating a candidate bioactive agent that causes the altered phenotype. Additionally, cells formed according to the described methods are also encompassed by the invention.

The invention concerns the use of deleucocytation filters for defensin purification. More precisely, the invention concerns a method for purifying defensins, including the following steps: passing a blood sample on a deleucocytation filter; detaching the cells retained on the deleucocytation filter, inducing exocytosis of the defensins by those cells.

The invention provides a targeting carbon nanotube drug delivery system, and a preparation method and applications thereof. The drug delivery system comprises a conjugate and a drug carrying carbon nanotube that is combined with the conjugate in a non-covalent mode; wherein the conjugate comprises a modifying material that can enhance the water solubility and biocompatibility of the drug delivery system and a targeting molecule that is combined with the modifying material in a covalent mode; and the drug carrying carbon nanotube is composed of carbon nanotubes and drug molecules that adsorb on the surface of the carbon nanotubes. One step modification technology is adopted, the problems on purification and yield caused by multi-step modification are avoided; at the same time, the carbon nanotube and drug delivery system are enable to have water solubility, biocompatibility, and multi-functions; the exocytosis of drug resistant tumor cells on drug molecules is effectively overcome, a novel strategy is provided for overcoming multi-drug resistance of tumor cells, and thus the provided drug delivery system has a wide application prospect in the field of drug resistant tumor treatment.

The invention relates to a fusarium fujikuroi mutant strain- fusarium fujikuroi GA-347 ( Fusarium fujikuroi GA-347 ) bred through an ARTP mutagenesis technique and an application of the fusarium fujikuroi mutant strain. The strain can be applied to industrial production in a large scale. The strain is preserved in China Center for Type Culture Collection, the address is Wuhan University, the postcode is 430072, the preservation No. is CCTCC NO:M 2019378, and the preservation date is 20 May 2019. In the growth process of the strain, conidium is not generated, the strain is inoculated to a liquid seed culture medium, and after cells grow to be mature, the cells are switched to a fermentation culture medium, so that the fermentation level is greatly increased, and the yield of gibberellin achieves 22 times of that of wild bacteria and leads in the national level. The gibberellin is in exocytosis, can be totally obtained from fermentation liquid, solid-liquid separation is facilitated, andthe extraction yield is increased. Besides, the utilization rate of equipment of raw materials is increased, the production cost is greatly reduced, and the strain has obvious economic benefits and social benefits.

The invention discloses a method for optimizing a signal peptide and improving exocytosis expression of trypsin, belonging to the technical field of genetic engineering. The signal peptide is fused with trypsin to express 8 types of pichia pastoris exocytosis signal peptides, and a starter (pAOX) is induced by methanol to express regrouped trypsin on pichia pastoris GS115 chromosome. Compared with the original alpha-factor signal peptide, the enzyme activity of the trypsin of the alpha mf signal peptide is improved by 2.75 times, and the problem that the exocytosis amount of the trypsin is low can be solved. By utilizing the method to produce the trypsin, the yield is high, the process is simplified, and the industrial application is convenient to realize.

The invention provides a gene knockout Escherichia coli beneficial to recombinant protein exocytosis and application thereof, relating to the field of modification of Escherichia coli genetic group genes. The gene knockout Escherichia coli beneficial to recombinant protein exocytosis is prepared by knocking out lipopolysaccharide synthesis related genes in Escherichia coli. The invention also provides a construction method of the gene knockout Escherichia coli and application of the gene knockout Escherichia coli in preparing extracellular soluble proteins. The preparation method is simple, and has the advantages of high efficiency and low cost. After the lipopolysaccharide-synthesized related genes are knocked out, the permeability of the pericellular membrane is enhanced, thereby obviously enhancing the recombinant protein exocytosis.

Compounds of general formula (I): R₁—W_n—X_m-AA₁-AA₂-AA₃-AA₄-AA₅-AA₆-AA₇-Y_p—Z_q—R₂, their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.

Compounds of general formula (I): R₁-W_n-X_m-AA₁-AA₂-AA₃-AA₄-AA₅-AA₆-AA₇-AA₈-AA₉-Y_p-Z_q-R₂ (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.

The invention provides a novel monoacyl-diacyl lipase Mdl (9), and a gene mdl (9) for coding the monoacyl-diacyl lipase. The amino acid sequence of the monoacyl-diacyl lipase is shown in SEQ ID No.2, and the nucleotide sequence for coding the monoacyl-diacyl lipase gene is shown in SEQ ID No.1. An experiment indicates that the monoacyl-diacyl lipase Mdl (9) has high activity of hydrolyzing monoacylglyceride and diacylglyceride. The invention also provides a method for secreting an expression carrier and effectively expressing the lipase in Pichia pastoris. By using the method, the expressed monoacyl-diacyl lipase can be effectively secreted out of cells, thereby lowering the cost for separation and purification and enhancing the expression efficiency. Under the condition of shake culture, when methanol is used as an inducer for induction culture, the exocytosis quantity can reach 660 mg/L; and when glycerin monostearate is used as a substrate, the enzyme activity reaches 2700 U/ml. The invention lays foundation for industrial application of the monoacyl-diacyl lipase.

The invention relates to methods and compositions which utilize the emission of light to monitor changes in microenvironments involving cells. The invention is especially useful for monitoring exocytotic activity such as detecting quantal release of synaptic vesicles. Fusion proteins of Cypridina luciferase and synaptotagmin-I or VAMP/synaptobrevin-2 were targeted to synaptic vesicles and, upon exocytosis, formed light-emitting complexes with luciferin present in the extracellular medium. Photon emissions in the presence of a depolarizing stimulus can be observed with these systems. pH-sensitive mutants of green fluorescent protein are also provided, which are useful for visualizing exocytosis and for imaging and measuring the pH of intracellular compartments.

The invention relates to a construction method of corynebacterium glutamicum engineering bacteria for high production of L-lysine. According to the method, the engineering bacteria are constructed by inactivating an NCgl1221 gene of corynebacterium glutamicum, wherein the nucleotide sequence of an NCgl1221 gene encoding frame is shown as SEQ ID NO. 1. The invention provides a construction method of a corynebacterium glutamicum strain for high production of the L-lysine; the constructed strain can obviously decrease glutamicum exocytosis due to the inactivation of the endogenous gene NCgl1221; compared with a wild strain, the strain can be used for producing high-concentration L-lysine and can effectively reduce the content of glutamicum which is a byproduct of a fermentation liquor; and the strain, as an L-lysine production strain, can further reduce production cost and purification cost.

The invention discloses a method for improving the exocytosis level of a recombinant protein of escherichia coli based on dacA, relating to the fields of gene engineering and fermentation engineering. By virtue of overexpression of a D-alanyl-D-alanine carboxypeptidase gene, the recombinant escherichia coli with the recombinant protein with the exocytosis level in overexpression is obtained. By virtue of the method, the secretion capacity of the recombinant protein of the escherichia coli can be remarkably improved. By utilizing amylase as a mode recombinant protein, the content of extracellular recombinant amylase of the escherichia coli is increased from 8.54% of a control group to 51.77%. The method has important guiding significance to the efficient secretion and production of the recombinant protein in the escherichia coli.

Described is a method for screening for alterations in exocytosis of a population of cells. The cells are sorted by a FACS machine by assaying for alterations in at least three of the properties selected from the group consisting of light scattering, fluorescent dye uptake, fluorescent dye release, annexin granule binding, surface granule enzyme activity, and the quantity of granule specific proteins. Methods for screening for bioactive agents capable of modulating exocytosis in a cell are also described. The methods provide for reduced background and increased specificity without increasing the time or steps involved in assaying for exocytosis.

The present invention relates to a novel cell based sensor useful for drug discovery that comprises a cell line with professional regulated exocytosis of secretory granules transfected with a protease as a reporter polypeptide stored in the regulated secretory granules of the cell line with professional regulated exocytosis and having either an endogenous or a heterologous molecule as a modulator of regulated secretory granules exocytosis, such said granule stored protease reporter having at least: a high resistance to conditions already present inside the granules such as low pH and proteolysis by other proteases; enzymatic activity after exocytosis; a highly specific cleavage sequence; a very low level of secretion under unstimulated or basal conditions; and a high signal to background activity in a media compatible with cell culture viability and granule exocytosis for a high throughput robust and sensitive detection.